France· FR:62768220
LAMPRENE 50 mg, capsule molle
A clofazimine product containing clofazimine, registered in France by NOVARTIS PHARMA. The same ATC class is registered in 7 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Clofazimine is registered in 7 of 19 countries.
Countries holding a registration under ATC J04BA01 (clofazimine), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 5 of them publish a price we can compare per daily dose
Clofazimine · ATC J04BA01
7 / 19 countries
- Czechiaprice
- Franceprice
- Japan
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CLOFAZIMINE
- Manufacturer
- NOVARTIS PHARMA
- Country
- France (FR)
- ATC code
- J04BA01
- ATC class
- Clofazimine
- Defined daily dose
- 0.1 g, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009560281531 flacon(s) polyéthylène de 100 capsule(s)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
158 interactions on record for clofazimine.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clofazimine · interactions on record
158 records
- 37 severe
- 119 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Clofazimine in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/905eb1ad-b8be-448e-aa9c-db1e2f51bf0f GET /v1/drugs/905eb1ad-b8be-448e-aa9c-db1e2f51bf0f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62768220",
"date_amm": "1997-03-28",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CLOFAZIMINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "capsule molle",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about clofazimine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.